SCHEMBL20028530

SCHEMBL20028530

CCOC(=O)c1cc(C)nn1-c1ccc(CO)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.50
ALDH1A1 P00352 4/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
POLB P06746 2/20 0.50
MAPT P10636 3/20 0.47
LMNA P02545 2/20 0.47
NPSR1 Q6W5P4 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
HTT P42858 2/20 0.45
USP2 O75604 1/20 0.45
HPGD P15428 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
NPY1R P25929 1/20 0.45
NPY2R P49146 1/20 0.45
STAT1 P42224 1/20 0.44
PDE4D Q08499 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18865511 0.88 KMT2A (0.52) KMT2AALDH1A1SMN1; SMN2POLBMAPT
SCHEMBL1877271 0.86 SMN1; SMN2 (0.52) KMT2AALDH1A1SMN1; SMN2POLBMAPT
SCHEMBL20028223 0.86 KMT2A (0.53) KMT2AALDH1A1SMN1; SMN2POLBMAPT
SCHEMBL14217732 0.85 PDE4D (0.60) KMT2AALDH1A1SMN1; SMN2POLBLMNA
SCHEMBL8511661 0.85 KMT2A (0.60) KMT2AALDH1A1SMN1; SMN2POLBMAPT
SCHEMBL5344577 0.85 MAPT (0.53) KMT2AALDH1A1SMN1; SMN2POLBMAPT
SCHEMBL7373266 0.85 SMN1; SMN2 (0.51) KMT2AALDH1A1SMN1; SMN2POLBMAPT
SCHEMBL6422295 0.85 KMT2A (0.65) KMT2AALDH1A1SMN1; SMN2POLBMAPT
SCHEMBL1873573 0.84 PDE4D (0.61) KMT2AALDH1A1SMN1; SMN2POLBMAPT
SCHEMBL20028496 0.83 SMN1; SMN2 (0.52) KMT2AALDH1A1SMN1; SMN2POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 US disclosed
US-10894776-B2 2021-01-19 US disclosed
WO-2018064119-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. (US) 2018-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 KMT2A 4418/4885ALDH1A1 4193/4885SMN1; SMN2 200/4885
US-10894776-B2 CAPNS1, CAPN9, CAPN2 KMT2A 4469/4885ALDH1A1 4421/4885SMN1; SMN2 263/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 KMT2A 4418/4885ALDH1A1 4193/4885SMN1; SMN2 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.